BioWorld International Correspondent
PARIS GenOway SA signed a nonexclusive agreement with the French pharmaceutical company Servier for the in vivo validation of a number of therapeutic gene targets.
At the same time, Lyon-based GenOway is engaged in another funding round to raise EUR6 million (US$5.4 million) from a group of European venture capital funds and financial institutions.
The deal provides for GenOway to validate gene targets identified by Servier using its proprietary target validation platform to predict the therapeutic potential of those targets for treating human disease. The financial terms of the agreement were not disclosed, nor were the …
No comments:
Post a Comment